Fondation Ophtalmologique Adolphe de Rothschild

2 marketed · 3 in Phase 3

Quick facts

Marketed products

Budesonide Nasal
injection of NMBA · Anesthesia
NMBA (neuromuscular blocking agent) injection causes temporary paralysis of skeletal muscles by blocking acetylcholine at the neuromuscular junction.

Phase 3 pipeline

addition of rituximab if recurrence
immediate treatment with corticosteroids · Ophthalmology / Immunology
Corticosteroids suppress immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Ocrelizumab Injection [Ocrevus] · Immunology / Neurology
Ocrelizumab is a monoclonal antibody that depletes B cells by binding to CD20, reducing immune-mediated inflammation and demyelination.

Phase 2 pipeline

Administration of dornase alfa · Respiratory
Dornase alfa is a recombinant form of human deoxyribonuclease I that breaks down DNA in the extracellular matrix of cystic fibrosis sputum, reducing its viscosity.
Daily infusion of dornase alfa · Pulmonary/Respiratory
Dornase alfa is a recombinant human DNase that breaks down extracellular DNA in mucus to reduce viscosity and improve clearance.

Phase 1 pipeline

Atropine 0.05% eyedrops

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Fondation Ophtalmologique Adolphe de Rothschild

What are Fondation Ophtalmologique Adolphe de Rothschild's marketed drugs?

Top marketed products include Budesonide Nasal, injection of NMBA.

What is Fondation Ophtalmologique Adolphe de Rothschild's pipeline?

Fondation Ophtalmologique Adolphe de Rothschild has 3 drugs in Phase 3, 2 in Phase 2, 1 in Phase 1. Late-stage candidates include addition of rituximab if recurrence, immediate treatment with corticosteroids, Ocrelizumab Injection [Ocrevus].

Budesonide Nasal
injection of NMBA · Anesthesia
Sector hub: All tracked pharma companies